JP7066679B2 - 認知症の処置 - Google Patents

認知症の処置 Download PDF

Info

Publication number
JP7066679B2
JP7066679B2 JP2019511720A JP2019511720A JP7066679B2 JP 7066679 B2 JP7066679 B2 JP 7066679B2 JP 2019511720 A JP2019511720 A JP 2019511720A JP 2019511720 A JP2019511720 A JP 2019511720A JP 7066679 B2 JP7066679 B2 JP 7066679B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
composition according
acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526571A5 (enExample
JP2019526571A (ja
Inventor
ミシェル ウィスチク，クロード
オラフ スケルター，ビョルン
ジュード ウィスチク，デイモン
マービン デイビッド ストーレイ，ジョン
Original Assignee
ウィスタ ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィスタ ラボラトリーズ リミテッド filed Critical ウィスタ ラボラトリーズ リミテッド
Publication of JP2019526571A publication Critical patent/JP2019526571A/ja
Publication of JP2019526571A5 publication Critical patent/JP2019526571A5/ja
Application granted granted Critical
Publication of JP7066679B2 publication Critical patent/JP7066679B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Valve Device For Special Equipments (AREA)
JP2019511720A 2016-09-01 2017-08-25 認知症の処置 Active JP7066679B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1614834.8 2016-09-01
GBGB1614834.8A GB201614834D0 (en) 2016-09-01 2016-09-01 Treatment of dementia
PCT/EP2017/071437 WO2018041739A1 (en) 2016-09-01 2017-08-25 Treatment of dementia

Publications (3)

Publication Number Publication Date
JP2019526571A JP2019526571A (ja) 2019-09-19
JP2019526571A5 JP2019526571A5 (enExample) 2020-10-01
JP7066679B2 true JP7066679B2 (ja) 2022-05-13

Family

ID=57139937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511720A Active JP7066679B2 (ja) 2016-09-01 2017-08-25 認知症の処置

Country Status (17)

Country Link
US (1) US10842796B2 (enExample)
EP (1) EP3506904B1 (enExample)
JP (1) JP7066679B2 (enExample)
KR (1) KR102559354B1 (enExample)
CN (1) CN109890391B (enExample)
AU (1) AU2017318333B2 (enExample)
DK (1) DK3506904T3 (enExample)
ES (1) ES2847929T3 (enExample)
GB (1) GB201614834D0 (enExample)
HR (1) HRP20210162T1 (enExample)
MX (1) MX384442B (enExample)
MY (1) MY187564A (enExample)
PL (1) PL3506904T3 (enExample)
PT (1) PT3506904T (enExample)
SG (1) SG11201901125TA (enExample)
SI (1) SI3506904T1 (enExample)
WO (1) WO2018041739A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
MY162313A (en) 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
BR112021000802A2 (pt) * 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
CN120148902A (zh) 2018-09-05 2025-06-13 云顶道卫思诊断中心有限公司 神经系统变性疾病的网络方法
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
GB202006659D0 (en) * 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
ES2992641T3 (en) * 2020-05-05 2024-12-16 Wista Lab Ltd Methylthioninium compounds for use in the treatment of hypoxemia
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
EP4342451A1 (en) * 2022-09-22 2024-03-27 Galenicum Health SLU Pharmaceutical compositions and manufacturing methods thereof
US20240115579A1 (en) * 2022-09-22 2024-04-11 Galenicum Health S.L.U. Pharmaceutical compositions and manufacturing methods thereof
US20240300940A1 (en) * 2023-02-21 2024-09-12 Prosetta Biosciences, Inc. Phenothiazinyl Compounds and Uses
GB202500018D0 (en) 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528431A (ja) 2002-05-31 2005-09-22 ハー・ルンドベック・アクチエゼルスカベット アルツハイマー病を治療するためのｎｍｄａ−アンタゴニスト及びアセチルコリンエステラーゼ阻害剤の組み合わせ物
JP2009531403A (ja) 2006-03-29 2009-09-03 ウイスタ・ラボラトリーズ・リミテッド ３，７−ジアミノ−１０ｈ−フェノチアジン塩およびその使用
JP2009531405A (ja) 2006-03-29 2009-09-03 ウイスタ・ラボラトリーズ・リミテッド チオニニウム化合物およびその使用
JP2010530403A (ja) 2007-06-19 2010-09-09 ウイスタ・ラボラトリーズ・リミテッド 軽度認知障害を処置するためのフェノチアジン化合物
JP2010540606A (ja) 2007-10-03 2010-12-24 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの治療的使用
JP2013505926A (ja) 2009-09-24 2013-02-21 ウィスタ ラボラトリーズ リミテッド プロセス
JP2014505095A (ja) 2011-02-11 2014-02-27 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
MY162313A (en) 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
US9034890B2 (en) * 2006-11-15 2015-05-19 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
KR20170061177A (ko) 2009-09-24 2017-06-02 위스타 레보레이토리스 리미티드 결정질 메틸티오니늄 클로라이드（메틸렌 블루） 수화물
CN102936244B (zh) * 2012-12-04 2015-02-04 合肥工业大学 一种他克林-吩噻嗪异二联体类化合物及其制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528431A (ja) 2002-05-31 2005-09-22 ハー・ルンドベック・アクチエゼルスカベット アルツハイマー病を治療するためのｎｍｄａ−アンタゴニスト及びアセチルコリンエステラーゼ阻害剤の組み合わせ物
JP2009531403A (ja) 2006-03-29 2009-09-03 ウイスタ・ラボラトリーズ・リミテッド ３，７−ジアミノ−１０ｈ−フェノチアジン塩およびその使用
JP2009531405A (ja) 2006-03-29 2009-09-03 ウイスタ・ラボラトリーズ・リミテッド チオニニウム化合物およびその使用
JP2010530403A (ja) 2007-06-19 2010-09-09 ウイスタ・ラボラトリーズ・リミテッド 軽度認知障害を処置するためのフェノチアジン化合物
JP2010540606A (ja) 2007-10-03 2010-12-24 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの治療的使用
JP2013505926A (ja) 2009-09-24 2013-02-21 ウィスタ ラボラトリーズ リミテッド プロセス
JP2014505095A (ja) 2011-02-11 2014-02-27 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Curr Treat Options Neurol，2014年，16:319，pp.1-14，DOI 10.1007/s11940-014-0319-0
FEBS Letters，2009年，583，pp.2419-2424
J. Neurochem，2016年，138(Suppl.1)，pp.211-221
Journal of Biological Chemistry，2015年，290(17)，pp.10862-10875

Also Published As

Publication number Publication date
AU2017318333B2 (en) 2023-05-11
GB201614834D0 (en) 2016-10-19
JP2019526571A (ja) 2019-09-19
PL3506904T3 (pl) 2021-07-26
ES2847929T3 (es) 2021-08-04
CN109890391B (zh) 2023-01-31
SI3506904T1 (sl) 2021-03-31
EP3506904A1 (en) 2019-07-10
MX2019002429A (es) 2019-07-08
PT3506904T (pt) 2021-02-02
US10842796B2 (en) 2020-11-24
CN109890391A (zh) 2019-06-14
KR102559354B1 (ko) 2023-07-26
MX384442B (es) 2025-03-14
AU2017318333A1 (en) 2019-04-18
MY187564A (en) 2021-09-30
DK3506904T3 (da) 2021-01-04
WO2018041739A1 (en) 2018-03-08
SG11201901125TA (en) 2019-03-28
KR20190045273A (ko) 2019-05-02
EP3506904B1 (en) 2020-12-09
US20190192530A1 (en) 2019-06-27
HRP20210162T1 (hr) 2021-03-19
CA3034625A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
KR102559354B1 (ko) 치매 치료
KR101918745B1 (ko) 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
KR101918669B1 (ko) 신경 장애 치료용 신규 조성물
CA2884781A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
CN105744932A (zh) 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物
AU2016319107A1 (en) Methods of treating neurodegenerative disorders in a particular patient population
CN116531386A (zh) 二氨基吩噻嗪的给药和剂量
KR20070084123A (ko) 양극성 장애 및 관련 증상의 치료
CA3238102A1 (en) Treating liver disorders with an ssao inhibitor
CA3034625C (en) Treatment of dementia
JP6797691B2 (ja) ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途
HK40003690B (en) Treatment of dementia
HK40003690A (en) Treatment of dementia
AU2018258970B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
JP2025500088A (ja) Ｆｅｎｍ及びアセチルコリンエステラーゼ阻害剤をベースとする新規相乗的組合せ
HK40071665A (en) Treating behavioral and psychological symptoms in dementia patients
CN116635034A (zh) 用于治疗人低胆碱能障碍的药物组合
JP2023544224A (ja) ヒト低コリン作動性障害の処置のための医薬の組合せ
CN114901282A (zh) 在痴呆患者中治疗行为和精神症状
AU2019211135A1 (en) Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220427

R150 Certificate of patent or registration of utility model

Ref document number: 7066679

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250